• 1
    Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001; 7: 11811193.
  • 2
    Vasquez EM. Sirolimus: a new agent for prevention of renal allograft rejection. Am J Health Syst Pharm 2000; 57: 437448
  • 3
    Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660665.
  • 4
    Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 12521260.
  • 5
    Kahan BD, Podbielski J, Napoli KL, et al. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 10401046.
  • 6
    Khanna AK. Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. Transplantation 2000; 70: 690694.
  • 7
    Watson CJE, Friend PJ, Jamieson NV, et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999; 67: 505509.
  • 8
    Trotter JF, Wachs M, Bak T, et al. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl 2001; 7: 343351.
  • 9
    Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation 1999; 67: 10361042.
  • 10
    Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicenter study. Lancet 2000; 356: 194202.
  • 11
    Kneteman NM, Meeberg G, Bonar S, et al. Sirolimus (SRL) immunosuppression for liver transplantation in the presence of malignancy [Abstract]. Presented at European Society for Organ Transplantation, 9th Congress, 1999; Oslo, Norway.
  • 12
    McAlister VC, Peltekian KM, Malatjalian DA, et al. Orthotopic liver transplantation using low-dose tacrolimus and sirolimus. Liver Transpl 2001; 7: 701708.
  • 13
    Guilbeau J. Delayed wound healing with sirolimus after liver transplant. Ann Pharmacother 2002; 36: 13911395.
  • 14
    Wiesner, R for the Rapamune Liver Transplant Study Group. The safety and efficacy of sirolimus and low-dose tacrolimus vs. tacrolimus in de novo orthotopic liver transplant recipients: results from a pilot study [Abstract]. Hepatology 2002; 36: 208A.
  • 15
    Kneteman N, Bigam D, Al-Saghier M, et al. Liver transplantation with a steroid-free, low-toxicity immunosuppressive protocol [Abstract]. Am J of Transplantation 2002; 2 (Suppl 3): 197.
  • 16
    Dunkelberg JC, Trotter JF, Wachs M, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery thrombosis or wound complications. Liver Transpl 2003; 9: 463468.